Alpco Home Page
New: Calprotectin Immunoturbidimetric Assay will take your testing to the next level. Learn more.Supporting your work with life science and clinical testing productsVIEW ALL LIFE SCIENCE PRODUCTSVIEW ALL CLINICAL DIAGNOSTIC PRODUCTS
Tips & Tricks
The Enzyme-Linked Immunosorbent Assay (ELISA) is a proven sensitive method for detecting and quantifying specific biomarkers in a wide range of clinical and research samples. The accuracy and precision of ELISAs can be affected by many factors, including pipetting, washing, and sample-handling techn...
Company Overview
Accuracy and Efficiency. Together.We are a leading global developer and provider of innovative molecular and immunodiagnostic products focused on Infectious and Gastroenterological Diseases. We are a trusted partner creating value for research and clinical laboratories with high-quality, user-frien...
Quality
Quality Policy and Standards“ALPCO is committed to producing in vitro diagnostic devices that exceed its customers’ expectations. This is accomplished by maintaining an effective quality management system and operating in compliance with its rigorous requirements. This commitment is evidenced by the...
Differentiating Gastrointestinal Pathogens from IBD and IBS
Gastrointestinal (GI) disorders such as inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS), as well as infections from GI pathogens can present very similar symptoms. A host of tests have been developed to aid in the differentiation between IBD and IBS, such as calprotectin and lact...
Complement System Webinar
Dr. Jörgen Wieslander from our partner, Euro Diagnostica, discusses functional assessment of all three pathways of the complement system.
https://www.youtube.com/watch?v=afJwUGoN99M
Complement System Solutions for Drug Development and Clinical Research
Datasheet: Complement System Immunoassays
Download
The complement system is essential to innate immunity which protects from chronic, autoimmune, and infectious disease. There are three distinct pathways of complement activation: classical, lectin/MBL, and alternative. Each leads...
ALPCO and Cisbio US, Inc. Announce Sales and Distribution Agreement
Date: July 1, 2015
ALPCO is pleased to announce a strategic account sales and distribution agreement with Cisbio US, Inc. Cisbio will now have exclusive access to ALPCO’s high quality STELLUX® Chemiluminescence and colorimetric Diabetes and Obesity assay portfolio in order to provide these produc...
Simplify Stool Sample Processing
Introduction
We understand the challenges facing lab managers and directors who need to continuously improve workflow efficiency and implement new tests and technologies to be competitive. Our unique extraction method can be used with a portfolio of targeted stool markers. This allows your lab to s...
Stool-Based Biomarkers to Differentiate Between IBD and IBS
What are IBD and IBS?
Inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS) are two different gastrointestinal tract issues affecting millions of people every day. Although there is some overlap between symptoms of IBD and IBS, differences still remain in regards to pathologies, risks...
ALPCO Releases a New Broad Range Periostin ELISA
ALPCO is now offering a new broad range Periostin ELISA that has been optimized to detect all known splicing forms of human periostin. The Periostin ELISA is highly characterized with a full validation package, and offers great reproducibility and precision. Not only are all standards and controls i...
The Changing Roles of Bone Remodeling Biomarkers
Introduction
Bones are traditionally known for their support, protection and movement properties, as well as their role in the processes of mineral balance and blood cell production. Research supports that bones do more than they were originally recognized for. Previous research investigating osteo...
[Infographic] The Benefits of Therapeutic Drug Monitoring for IBD
The Burden of Inflammatory Bowel Disease in the US and Canada
More than 1 million people in the US and 200,000 people in Canada are currently living with inflammatory bowel disease (IBD). This number is projected to grow exponentially over the next 10 years1,2. As the prevalence of IBD increases, s...
The Impact of Adiponectin in NAFLD and NASH Research
Date: March 7, 2017
Lately, nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) have been widely discussed in both the clinical and research communities. Some of the focus has been related to alternative research methods that can improve diagnostic and monitoring meth...
Investigating Immunogenicity of IBD Biologics
Biologics have been commonly prescribed as therapies for inflammatory bowel disease (IBD) since the late 1990s. However, research demonstrates that not all individuals respond to the first biologic taken and many lose response over time1. As a result, there is a great need to explore the immunogenic...
IBS Awareness Month: Facts About IBS
In support of IBS Awareness Month, we created this short video to share some important facts about IBS and spread the word about this incurable, debilitating disorder.
Be sure to like and share our video to show your support of IBS Awareness Month!
https://youtu.be/6K_55Bg922s
Quick Facts Abo...
Introducing the STELLUX® Chemi Active GLP-1 (7-36) amide ELISA
Watch our video to learn more about the STELLUX® Chemi Active GLP-1 (7-36) amide ELISA and how you can now measure this incretin hormone with confidence.
https://www.youtube.com/watch?v=Chu3VhEEpt0&t=3s
The STELLUX® Chemi Active GLP-1 (7-36) amide ELISA features increased sensitivity to ac...
ALPCO’s Quality Management System Receives ISO 13485:2016 Certification
October 8, 2018
ALPCO recently announced that its quality management system received the distinguished ISO 13485:2016 certification from Intertek. ALPCO’s certification applies to the design, development, manufacture, and distribution of in vitro diagnostic reagents and kits.
The Internati...
Ampersand Capital Partners Acquires American Laboratory Products Company
FOR IMMEDIATE RELEASE
Salem, NH – September 21, 2020: American Laboratory Products Company, Ltd. (ALPCO), a specialty in vitro diagnostics company, today announced the majority recapitalization of the company by Ampersand Capital Partners. Ampersand’s investment will be used to support ALPCO’s wo...
Enhance Your Lab’s Molecular GI Portfolio
Molecular GI testing for bacteria such as salmonella, vibrio, and E. coli, and viral pathogens including norovirus and rotavirus, is instrumental in the diagnosis and treatment of infection and dysbiosis. In addition, many gastrointestinal disorders often require protein biomarker tests to aid in ac...
GI Testing
Calprotectin Chemiluminescence ELISA (80-CALPHU-CH01)
The Calprotectin Chemiluminescence ELISA is an in vitro diagnostic chemiluminescent assay intended for the quantitative measurement of fecal calprotectin, a neutrophilic protein that is a marker of intestinal mucosal inflammation, in human sto...
Preparing for a Successful Assay Validation
On-boarding of new assays is critical for menu expansion and revenue growth, but the validation of a new assay requires a significant investment of time and resources. Proper planning can reduce errors and delays, minimizing validation time and reducing the impact on normal operations. Below are a f...
Next-Gen Multiplex Allergy Testing with MADx
ALPCO has partnered with MacroArray Diagnostics, MADx, to offer a comprehensive testing solution for IgE-based allergies. MADx’s multiplex allergy test incorporates allergens covering 99% of globally relevant allergens, including pollen, pet allergens, dust mites, insect venom, foods, and mo...